



# Metabolomics Amino Acid Mixtures

For Identification and Quantification



Amino acids play critical roles in biological functions as both building blocks of peptides/proteins and intermediates of various metabolic pathways (e.g., citric acid cycle, urea cycle). These compounds are also reported to influence the pathogenesis and propagation of metabolic disorders/disease. Other areas of research investigate amino acids in biomarker and drug-discovery studies.

**To aid continued development and application, Cambridge Isotope Laboratories, Inc. (CIL) has formulated new mixtures of stable isotope-labeled amino acids.** These include a mix of the canonical amino acids (MSK-CAA-1) and a mix of rare or unnatural noncanonical amino acids (MSK-NCAA-1). The mixes are well characterized for use in quality control and qualification/quantification studies using targeted or untargeted LC-MS methodologies.

**MSK-CAA-1:** Stable isotope-labeled canonical amino acid mix composition. Reconstitution with 1 mL solvent results in concentrations of 2.5 mM (exception L-cystine: 1.25 mM).

Compound	Abbrev.	Label and Enrichment
Glycine	Gly	<sup>13</sup> C <sub>2</sub> , 99%; <sup>15</sup> N, 99%
L-Alanine	Ala	<sup>13</sup> C <sub>3</sub> , 99%; <sup>15</sup> N, 99%
L-Arginine-HCl	Arg	<sup>13</sup> C <sub>6</sub> , 99%; <sup>15</sup> N <sub>4</sub> , 99%
L-Asparagine-H <sub>2</sub> O*	Asn	<sup>13</sup> C <sub>4</sub> , 99%; <sup>15</sup> N <sub>2</sub> , 99%
L-Aspartic Acid	Asp	<sup>13</sup> C <sub>4</sub> , 99%; <sup>15</sup> N, 99%
L-Cystine	Cys-Cys	<sup>13</sup> C <sub>6</sub> , 99%; <sup>15</sup> N <sub>2</sub> , 99%
L-Glutamic Acid	Glu	<sup>13</sup> C <sub>5</sub> , 99%; <sup>15</sup> N, 99%
L-Glutamine*	Gln	<sup>13</sup> C <sub>5</sub> , 99%; <sup>15</sup> N <sub>2</sub> , 99%
L-Histidine-HCl·H <sub>2</sub> O	His	<sup>13</sup> C <sub>6</sub> , 97-99%; <sup>15</sup> N <sub>3</sub> , 97-99%
L-Isoleucine	Iso	<sup>13</sup> C <sub>6</sub> , 99%; <sup>15</sup> N, 99%
L-Leucine	Leu	<sup>13</sup> C <sub>6</sub> , 99%; <sup>15</sup> N, 99%
L-Lysine-2HCl	Lys	<sup>13</sup> C <sub>6</sub> , 99%; <sup>15</sup> N <sub>2</sub> , 99%
L-Methionine	Met	<sup>13</sup> C <sub>5</sub> , 99%; <sup>15</sup> N, 99%
L-Phenylalanine	Phe	<sup>13</sup> C <sub>9</sub> , 99%; <sup>15</sup> N, 99%
L-Proline	Pro	<sup>13</sup> C <sub>5</sub> , 99%; <sup>15</sup> N, 99%
L-Serine	Ser	<sup>13</sup> C <sub>3</sub> , 99%; <sup>15</sup> N, 99%
L-Threonine	Thr	<sup>13</sup> C <sub>4</sub> , 97-99%; <sup>15</sup> N, 97-99%
L-Tryptophan*	Trp	<sup>13</sup> C <sub>11</sub> , 99%; <sup>15</sup> N <sub>2</sub> , 99%
L-Tyrosine	Tyr	<sup>13</sup> C <sub>9</sub> , 99%; <sup>15</sup> N, 99%
L-Valine	Val	<sup>13</sup> C <sub>5</sub> , 99%; <sup>15</sup> N, 99%

\*Compounds absent in MSK-A2-1.2. This amino acid mix comprises 17 compounds and is supplied as a 1.2 mL solution (in 0.1 M HCl).

**MSK-NCAA-1:** Stable isotope-labeled noncanonical amino acid mix composition. Reconstitution with 1 mL solvent results in concentrations of 2.5 mM.

Compound	Abbrev.	Label and Enrichment
β-Alanine	β-Ala	<sup>13</sup> C <sub>3</sub> , 98%; <sup>15</sup> N, 96-99%
L-Azidohomoalanine-HCl	hAHA	1,2,3,4- <sup>13</sup> C <sub>4</sub> , 99%; 2,4- <sup>15</sup> N <sub>2</sub> , 98%
L-Citrulline	Cit	1,2,3,4,5- <sup>13</sup> C <sub>5</sub> , 98%
L-Dihydroxyphenylalanine	DOPA	1- <sup>13</sup> C, ring- <sup>13</sup> C <sub>6</sub> , 99%
L-Homoarginine-HCl	Harg	<sup>13</sup> C <sub>7</sub> , 98%; <sup>15</sup> N <sub>4</sub> , 98%
L-Ornithine-HCl	Orn	<sup>13</sup> C <sub>5</sub> , 98%
Sarcosine-HCl	Sar	<sup>13</sup> C <sub>3</sub> , 99%; <sup>15</sup> N, 98%

Catalog No.	Description
MSK-CAA-1	Canonical Amino Acid Mix
MSK-NCAA-1	Noncanonical Amino Acid Mix
MSK-A2-1.2	Metabolomics Amino Acid Mix

Unlabeled mixtures are also available. Please inquire.

## References

Lu, Y.; Wang, Y.; Liang, X.S.; et al. **2019**. Serum amino acids in association with prevalent and incident type 2 diabetes in a Chinese population. *Metabolites*, 9(1), 14.

Haines, N.R.; Manoharan, N.; Olson, J.L.; et al. **2018**. Metabolomics analysis of human vitreous in diabetic retinopathy and rhegmatogenous retinal detachment. *J Proteome Res*, 17(7), 2421-2427.

Mehta, K.Y.; Wu, H.J.; Menon, S.S.; et al. **2017**. Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. *Oncotarget*, 8(40), 68899-68915.

Chen, W.W.; Freinkman, E.; Sabatini, D.M. **2017**. Rapid immunopurification of mitochondria for metabolite profiling and absolute quantification of matrix metabolites. *Nat Protoc*, 12(10), 2215-2231.

